BusinessBioStem Technologies Inc. Announces Intent to Acquire GIINTBy Nasdaq OMXFeb 27, 2018, 1:27 AM UTC
BusinessBioStem Technologies Inc. Applies for Uplisting to the OTCQX MarketBy Nasdaq OMXFeb 16, 2018, 2:44 PM UTC
BusinessRegentys, Cook Biotech to Collaborate in Developing, Delivering Unique Ulcerative Colitis TreatmentBy Nasdaq OMXFeb 14, 2018, 12:00 PM UTC
BusinessPredictive Technology Group Finalizes Letter of Intent to Acquire FlagshipHealth GroupBy Nasdaq OMXJan 9, 2018, 6:00 PM UTC
BusinessRegentys Names Dr. John F. Howes Vice President of Clinical and Regulatory AffairsBy Nasdaq OMXJan 9, 2018, 12:31 PM UTC
BusinessRegenerative Medicine Foundation Proudly Presents The 2018 "Stem Cell and Regenerative Medicine Action Award" HonoreesBy Nasdaq OMXDec 21, 2017, 1:23 AM UTC
BusinessBioStem Technologies, Inc. Files “Issuer Company-Related Action Notification” with the Financial Industry Regulatory Authority, Requesting Name and Symbol Change to BioBlue TechnologiesBy Nasdaq OMXNov 1, 2017, 4:26 PM UTC
BusinessInforma Pharma Intelligence and The Alliance for Regenerative Medicine Partner to Promote Education on Rapidly Advancing Regenerative TherapiesBy Nasdaq OMXOct 17, 2017, 1:58 PM UTC
